Value of thyroglobulin to 131I uptake ratio in selection of initial therapy dose of 131I in patients with differentiated thyroid carcinoma

被引:0
|
作者
Zerva, C. [1 ]
Koutsikos, J. [1 ]
Palestidis, C. [1 ]
Kounadi, E. [1 ]
Gerali, S. [1 ]
机构
[1] Alexandra Univ Hosp, Dept Nucl Med, GR-11528 Athens, Greece
来源
QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2006年 / 50卷 / 04期
关键词
differentiated thyroid carcinoma; thyroglobulin; I-131; uptake; I-131 ablative dose; therapy;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Aim To test the hypothesis that the ratio of thyroglobulin (Tg) to I-131 uptake in the thyroid bed during the immediate post-thyroidectomy work-up could be used before first I-131 treatment to detect patients with residual or metastatic thyroid cancer and justify the administration of a higher ablation dose in selected cases and a possibly better therapeutic effect. Methods. We retrospectively studied 293 patients with differentiated thyroid carcinoma that received their first I-131 treatment in our department. Patients with Tg > 100 ng/ml I-131 uptake > 10% and measurable Tg-specific autoantihodies, were excluded. According to the post-therapy total body scan (TBS), we divided them in 2 groups: group I, without metastases (negative TBS), and group II, with metastases (positive TBS). The ratio of Tg to I-131 uptake measured before the first I-131 treatment was calculated in both groups. Results. A total of 248 patients were included in the study;, 225 in group I and 23 in group II. Tg to I-131 uptake ratio was significantly lower in group I (mean 2.17 ng/ml/%, range 0-36), than in group II (mean 32.7 ng/mL/%, range 2.14-220), (P < 0.01). The sensitivity, specificity and accuracy (using a threshold ratio 7 ng/mL/% as normal) were all 95.6% for predicting a positive post-therapy TBS. Conclusion The use of a threshold ratio 7 ng/mL% as the upper limit of normal provides usefid information with higher sensitivity and specificity in identifying patients with metastatic disease creating the possibility for the selective use of higher initial iodine therapy doses.
引用
收藏
页码:348 / 354
页数:7
相关论文
共 50 条
  • [31] Comparing pre-therapeutic 124I and 131I uptake tests with intra-therapeutic 131I uptake in benign thyroid disorders
    Falk Gühne
    Christian Kühnel
    Martin Freesmeyer
    Endocrine, 2017, 56 : 43 - 53
  • [32] Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma
    Min, JJ
    Chung, JK
    Lee, YJ
    Jeong, JM
    Lee, DS
    Jang, JJ
    Lee, MC
    Cho, BY
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (05) : 639 - 645
  • [33] The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma
    Thies, Elena-Daphne
    Tanase, Karina
    Maeder, Uwe
    Luster, Markus
    Buck, Andreas K.
    Haenscheid, Heribert
    Reiners, Christoph
    Verburg, Frederik A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (12) : 2281 - 2290
  • [34] Role of 131I in low-risk differentiated thyroid cancer
    Vallejo, J. A.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2023, 42 (01): : 33 - 37
  • [35] The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma
    Elena-Daphne Thies
    Karina Tanase
    Uwe Maeder
    Markus Luster
    Andreas K. Buck
    Heribert Hänscheid
    Christoph Reiners
    Frederik A. Verburg
    European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41 : 2281 - 2290
  • [36] Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and 131I ablation
    Salvatore, B.
    Paone, G.
    Klain, M.
    Storto, G.
    Nicolai, E.
    D'Amico, D.
    Della Morte, A. M.
    Pace, L.
    Salvatore, M.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 52 (01): : 2 - 8
  • [37] Improved follow-up of patients with differentiated thyroid carcinoma The quantitative detection limit of 131I uptake in diagnostic scans
    Diessl, S.
    Verburg, F.
    Biko, J.
    Schryen, B.
    Reiners, C.
    Buck, A.
    Hanscheid, H.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2013, 52 (03): : 81 - 87
  • [38] Usefulness of second 131I treatment in biochemical persistent differentiated thyroid cancer patients
    Gambale, Carla
    Prete, Alessandro
    Contartese, Lea
    Torregrossa, Liborio
    Bianchi, Francesca
    Molinaro, Eleonora
    Materazzi, Gabriele
    Elisei, Rossella
    Matrone, Antonio
    EUROPEAN THYROID JOURNAL, 2023, 12 (06)
  • [39] 131I-chTNT-mediated radioimmunotherapy for non-uptaking 131I pulmonary metastases from differentiated thyroid carcinoma
    GAO Shi
    JI Tiefeng
    WEN Qiang
    CHEN Bin
    MA Qingjie
    CHEN Zuowei
    LIU Lin
    Nuclear Science and Techniques, 2013, 24 (06) : 59 - 63
  • [40] Dedifferentiation of differentiated thyroid carcinoma cell line FTC-133 is enhanced by 131I pretreatment
    Feng, Fang
    Wang, Hui
    Fu, Hongliang
    Wu, Shuqi
    Ye, Zhiyi
    Chen, Suyun
    Li, Jianing
    NUCLEAR MEDICINE AND BIOLOGY, 2011, 38 (07) : 1053 - 1058